Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin dose-escalation pharmacokinetics and safety study in tuberculosis
NL-OMON36271Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of moxifloxacin in Tuberculosis (TB), sponsored by University Medical Center Groningen. Primary endpoints: Bound AUC0-24h/MIC target attainment, Unbound AUC0-24h/MIC target attainment and 6 more. Started Jun 2011; status: active, not recruiting.
02
Drugs
moxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON36271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36271.